<DOC>
	<DOCNO>NCT01103518</DOCNO>
	<brief_summary>This Phase IV , randomize , double-blind , comparative study use two preparation ethinyl estradiol cyproterone acetate treatment menstrual irregularity hyper-androgenic origin .</brief_summary>
	<brief_title>Ethinyl Estradiol Cyproterone Acetate Irregular Menstruation</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Amenorrhea</mesh_term>
	<mesh_term>Hyperandrogenism</mesh_term>
	<mesh_term>Menstruation Disturbances</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Female subject Premenopausal subject 18 year old Medical history irregular menses last least 3 month Signature inform consent Pregnancy Use hormonal contraceptive within 3 month screen Primary bilateral oophorectomy Chemotherapy / radiotherapy within 6 month screen Hysterectomy Myotonic dystrophy Galactosemia Galactorrhea History tuberculosis schistosomiasis Elevated prolactin / significant laboratory alteration Diabetes Premature ovarian deficiency Sensitivity component drug formula</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Menstrual irregularity</keyword>
	<keyword>Menstruation disturbance</keyword>
	<keyword>Hyperandrogenism</keyword>
</DOC>